Novel medication strategies targeting brain mechanisms in pediatric ocd

This study aims to determine whether adding a medication called minocycline to

antidepressant treatment can help reduce symptoms of OCD. This study also aims to

learn more about the brains of children and adolescents with OCD.

 

Your child must be taking a stable dose of a serotonin reuptake inhibitor (SRI) in order to

participate in this study. During the 12 week study period, your child will continue to

take the SRI s/he is currently taking. Your child will also be given another medicine to

take which will be either minocycline or pill placebo (a pill with no medicine in it). There

is a two out of three chance that your child will receive minocycline instead of placebo.

You, your child, and the study doctor will not know whether your child is receiving

minocycline or placebo until after the study is over, but the information will be available

in case of a medical emergency.

 

Participants will be compensated for their participation. After the study period, follow-up

care including medication management will be provided for three additional months at no

cost to you.

Organization: 
Columbia University Medical Center/New York State Psychiatric Institute
Principal Investigator: 
Dr. Moira Rynn, M.D. and Dr. H. Blair Simpson
Eligibility Criteria: 

• 8 - 20 years

• Genders: both

• Key inclusion criteria: Primary diagnosis of OCD and currently on a stable and adequate dose of an SRI

 

Your child may be eligible to participate in this study if he/she is diagnosed with Obsessive-Compulsive Disorder.

Exclusion Criteria: 

• Lifetime diagnosis of: psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder, mental retardation, or substance/alcohol dependence

• Current diagnosis of major depressive disorder, attention-deficit hyperactivity disorder (ADHD), Tourette’s/Tic Disorder, or substance/alcohol abuse

• Diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)

• Active Suicidal Ideation

• Hoarding as the primary OCD symptom

• Pregnant, nursing, or planning to become pregnant

Contact: 
Amy Rapp, (212) 543-5592.
Location: 
New York, NY
State: 
New York

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Health Impact Award

Award for Excellence